ANTIDOTE Institute Info Session
Interested in the ANTIDOTE Institute? Join ACMT for an informative session on Friday, October 20th at 3 pm ET. Discover more about the program and how to apply!
About the ANTIDOTE Institute
The ANTIDOTE Institute is generously funded by NIH/NIDA (Grant No. 1R25DA058490) and presents a unique opportunity for fellows and junior faculty members to kickstart their journey in investigative research. Participants can expect to: begin cultivating their own research niche, build valuable connections with peers and seasoned investigators within their field, and acquire practical knowledge encompassing key aspects of establishing a successful research program. The institute spans two years and comprises:
- Focused, small-group sessions featuring moderated peer review, mentorship, and in-depth discussions on fundamental research topics.
- Personalized one-on-one mentorship with an accomplished medical toxicology investigator.
Furthermore, the program offers the potential for up to $25,000 in seed funding to bolster your research pursuits.
Feel free to reach out to us at firstname.lastname@example.org for any inquiries or clarifications. We look forward to assisting you on your journey with ANTIDOTE Institute!
Stephanie Carreiro, MD, PhD, FACMT
Associate Professor, Director of the Tox(In)novation Lab
University of Massachusetts Chan Medical School
Dr. Stephanie Carreiro is an emergency medicine physician, medical toxicologist, and digital health researcher. She is a 2009 graduate of New York Medical College, and completed her emergency medicine residency in 2013 at Brown University. She completed a medical toxicology fellowship in 2015, and recently received a PhD in Biomedical Sciences both at the University of Massachusetts. She is currently an Associate Professor, Director of the Tox(In)novation Lab, and Research Director in the Department of Emergency Medicine at University of Massachusetts Chan Medical School. Her current research program focuses on developing digital therapeutics for substance use disorder, understanding how patients use and engage with technology, and leveraging digital technology to promote health equity. She is the principal investigator multiple industry and federally funded research grants, including several awards from the National Institute on Drug Abuse and National Institute of Biomedical Imaging and Bioengineering.
Peter Chai, MD, MMS
Brigham and Women's Hospital
Dr. Peter R Chai is an assistant professor of emergency medicine and medical toxicology at Brigham and Women’s Hospital/Harvard Medical School, and affiliate research scholar at the Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology, and The Fenway Institute. He is also research faculty at the Dana Farber Cancer Institute. Dr. Chai’s research primarily involves the development and implementation of technological solutions that detect and respond to changes in disease. These translational projects ranges from design of novel robotic and sensor systems in animal models to human clinical trials to test the implementation of injectable and ingestible sensor systems and overlying behavioral science architecture to respond to disease states. Specifically, Dr. Chai is interested in applying ingestible electronic sensor systems to understand medication adherence in the context of substance use and HIV treatment/prevention. His work in developing ingestible sensors and their overlying behavioral interventions as closed loop systems to measure, reinforce and provide tools for PrEP and ART adherence has been funded by the National Institutes of Health and industry partners.